“An Unrelenting Disaster Zone”: Merck’s Alzheimer’s Drug Fails in Phase III Post author:Sam Post published:February 13, 2018 Post category:BioPharma Alzheimer’s drug development took another hit. Source: BioSpace You Might Also Like Johnson & Johnson Selling LifeScan Unit for $2.1 Billion March 15, 2018 G1 Therapeutics Appoints To Board Of Directors July 12, 2017 Mirati Therapeutics Reports Second Quarter 2017 Financial Results August 3, 2017
